Skip to main content

Table 2 Patient characteristics and laboratory parameters at the study inclusion

From: Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

 Arm A
(n = 9)
Arm B
(n = 7)
pvalue
Patients’ characteristics(m + SE)(m + SE) 
Age36.3 ± 6.7034.7 ± 6.920.643
Sex 
 Male6 (75.0)2 (25.0)0.131
 Female3 (37.5)5 (62.5) 
Weight (kg)53.2 ± 8.4349.1 ± 8.930.367
Body mass index (BMI)18.6 ± 3.0816.5 ± 2.880.182
Haemoglobin (g/dL)8.4 ± 1.9511.1 ± 3.510.062
Leucocytes (103/mL))5277 ± 53855928 ± 33040.783
Neutrophils (103/mL))3795 ± 36633638 ± 31340.929
Lymphocyte (103/mL))2417 ± 22241442 ± 4850.277
Monocytes (103/mL))400 ± 430271 ± 1790.472
AST (U/L)46.5 ± 24.2348.2 ± 33.100.905
ALT (U/L)41.2 ± 25.4332.8 ± 22.050.500
Creatinine (μmol/L)98.2 ± 22.0493.1 ± 21.960.652
Total cholesterol (mmol/L) T143.2 ± 30.30129.8 ± 25.910.368
HDL cholesterol (mmol/L)44.7 ± 23.6342.4 ± 16.840.827
Amylase (U/L)131.0 ± 71.3192.8 ± 53.280.266
Total bilirubin (μmol/L)3.3 ± 2.263.8 ± 2.330.696
Direct bilirubin (μmol/L)1.08 ± 0.851.45 ± 1.560.618
Lymphocytes CD4+ T (cells/μL)221.1 ± 154.75285.8 ± 175.390.446
Type of tuberculosis
 SPPT7 (50.0)7 (50.0)0.475
 SNPT2 (100.0)0 (0.0)
WHO HIV stage
 Stage 21/90/70.562
 Stage 38/97/7 
Opportunistic infections
 Yes5/93/70.500
 No4/94/7